Question · asked by 1 review
PERPHENAZINE vs LOW‐POTENCY ANTIPSYCHOTIC DRUGS: Acceptability of treatment ‐ leaving the study early
- Population
- patients with schizophrenia
- Intervention
- PERPHENAZINE
- Comparison
- LOW‐POTENCY ANTIPSYCHOTIC DRUGS
- Outcome
- Acceptability of treatment ‐ leaving the study early
It is very uncertain whether comparison 1: PERPHENAZINE changes acceptability of treatment ‐ leaving the study early due to any reason compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (very low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Comparison 1: PERPHENAZINE vs LOW‐POTENCY ANTIPSYCHOTIC DRUGS Acceptability of treatment ‐ leaving the study early due to any reason · patients with schizophrenia It is very uncertain whether comparison 1: PERPHENAZINE changes acceptability of treatment ‐ leaving the study early due to any reason compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (very low certainty). Perphenazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia (2014) · Cochrane Headline outcomes only | RR 0.78 [0.35, 1.76] | 3 studies · 323 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Perphenazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia 2014 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.